Analyst Price Target is $7.33
▲ +124.26% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Lyell Immunopharma in the last 3 months. The average price target is $7.33, with a high forecast of $11.00 and a low forecast of $4.00. The average price target represents a 124.26% upside from the last price of $3.27.
Current Consensus is
The current consensus among 3 polled investment analysts is to hold stock in Lyell Immunopharma. This rating has held steady since July 2022, when it changed from a Buy consensus rating.
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.